Company’s 36-month beta value is 1.47.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CERE is 87.15M, and currently, short sellers hold a 9.09% ratio of that floaft. The average trading volume of CERE on May 02, 2024 was 1.39M shares.
CERE) stock’s latest price update
The stock of Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) has decreased by -0.19 when compared to last closing price of 42.71. Despite this, the company has experienced a 1.74% gain in its stock price over the last five trading sessions. Investopedia reported 2023-12-07 that Cerevel Therapeutics Holdings (CERE) shares jumped more than 11% Thursday after AbbVie (ABBV) agreed to acquire the neuroscience drugmaker for about $8.7 billion.
CERE’s Market Performance
Cerevel Therapeutics Holdings Inc (CERE) has seen a 1.74% rise in stock performance for the week, with a 0.66% gain in the past month and a 1.74% surge in the past quarter. The volatility ratio for the week is 0.92%, and the volatility levels for the past 30 days are at 0.82% for CERE. The simple moving average for the past 20 days is 1.27% for CERE’s stock, with a 29.20% simple moving average for the past 200 days.
Analysts’ Opinion of CERE
Many brokerage firms have already submitted their reports for CERE stocks, with TD Cowen repeating the rating for CERE by listing it as a “Market Perform.” The predicted price for CERE in the upcoming period, according to TD Cowen is $45 based on the research report published on December 08, 2023 of the previous year 2023.
JP Morgan, on the other hand, stated in their research note that they expect to see CERE reach a price target of $25. The rating they have provided for CERE stocks is “Neutral” according to the report published on November 20th, 2023.
Piper Sandler gave a rating of “Overweight” to CERE, setting the target price at $33 in the report published on September 28th of the previous year.
CERE Trading at 1.82% from the 50-Day Moving Average
After a stumble in the market that brought CERE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.20% of loss for the given period.
Volatility was left at 0.82%, however, over the last 30 days, the volatility rate increased by 0.92%, as shares surge +0.71% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.87% upper at present.
During the last 5 trading sessions, CERE rose by +1.74%, which changed the moving average for the period of 200-days by +43.63% in comparison to the 20-day moving average, which settled at $42.11. In addition, Cerevel Therapeutics Holdings Inc saw 0.54% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERE starting from COLES N ANTHONY, who sale 50,000 shares at the price of $42.33 back on Apr 01 ’24. After this action, COLES N ANTHONY now owns 15,638 shares of Cerevel Therapeutics Holdings Inc, valued at $2,116,640 using the latest closing price.
COLES N ANTHONY, the Director of Cerevel Therapeutics Holdings Inc, sale 50,000 shares at $41.01 during a trade that took place back on Mar 04 ’24, which means that COLES N ANTHONY is holding 15,638 shares at $2,050,550 based on the most recent closing price.
Stock Fundamentals for CERE
Current profitability levels for the company are sitting at:
- -54.24 for the present operating margin
- 0.32 for the gross margin
The net margin for Cerevel Therapeutics Holdings Inc stands at -52.49. The total capital return value is set at -0.39. Equity return is now at value -72.44, with -38.29 for asset returns.
Based on Cerevel Therapeutics Holdings Inc (CERE), the company’s capital structure generated 0.4 points at debt to capital in total, while cash flow to debt ratio is standing at -0.76. The debt to equity ratio resting at 0.67. The interest coverage ratio of the stock is -31.12.
Currently, EBITDA for the company is -441.64 million with net debt to EBITDA at 1.19. When we switch over and look at the enterprise to sales, we see a ratio of 878.46. The receivables turnover for the company is 1.56for trailing twelve months and the total asset turnover is 0.01. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.92.
Conclusion
In a nutshell, Cerevel Therapeutics Holdings Inc (CERE) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
